07:00 , Jul 26, 2001 |  BC Extra  |  Financial News

De Novo raises EUR27.3 million

Molecular design play De Novo Pharmaceuticals ( Cambridge , U.K.) raised EUR27.3 million ($24 million) in a VC round led by Merlin Biosciences Fund, which put up EUR7.3 million. New investors included Life Science Partners;...
07:00 , Apr 24, 2000 |  BioCentury  |  Finance

Old-fashioned values

That generosity wasn't provided to Immunex (IMNX), however, which took a $3.4 billion haircut despite beating the Street consensus by a penny, reporting $0.06 EPS. First quarter sales of Enbrel to treat rheumatoid arthritis hit...
08:00 , Mar 6, 2000 |  BioCentury  |  Finance

Best of both worlds

U.K investors flocked to the double-dip genomics-antibody play offered up by Cambridge Antibody Technology (LSE:CAT), which leapt 2050p (112 percent) to 3875p on the coattails of its 10-year deal with Human Genome Sciences (HGSI) to...